Immunity to melanoma antigens: from self-tolerance to immunotherapy.
about
Regulation of T-cell Tolerance by Lymphatic Endothelial Cells.Tolerogenic properties of lymphatic endothelial cells are controlled by the lymph node microenvironment.The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?Interface of signal transduction inhibition and immunotherapy in melanoma.Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice.Evaluation of the sentinel immunized node for immune monitoring of cancer vaccinesLymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation.Strategies and challenges in eliciting immunity to melanoma.Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies.MHC class II presentation of gp100 epitopes in melanoma cells requires the function of conventional endosomes and is influenced by melanosomes.Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survivalCryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcomaPhase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.Rapid regression of a subset of class 1 uveal melanomas after Iodine-125 plaque radiotherapy suggests an inflammatory mechanism.Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens.Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.Intratumoral administration of secondary lymphoid chemokine and unmethylated cytosine-phosphorothioate-guanine oligodeoxynucleotide synergistically inhibits tumor growth in vivo.CD200 is induced by ERK and is a potential therapeutic target in melanoma.Trial watch: Peptide vaccines in cancer therapyImmunotherapy of melanoma: a critical review of current concepts and future strategies.Allogeneic tumor-cell-based vaccines secreting endoplasmic reticulum chaperone gp96.Targeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine.Multipeptide vaccination in cancer patients.Protein and non-protein biomarkers in melanoma: a critical update.The proteasome immunosubunits, PA28 and ER-aminopeptidase 1 protect melanoma cells from efficient MART-126-35 -specific T-cell recognition.Immunoproteasomes edit tumors, which then escapes immune recognitionA potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapyDevelopment of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases.FOXP3 expression is modulated by TGF‑β1/NOTCH1 pathway in human melanoma.
P2860
Q30300970-5F037E59-EDAF-4570-8FC9-3CF5F2E4D81FQ30414892-BB6DDD34-AE56-4E82-9B37-DCA8584500E0Q30423165-E36FC74E-D186-46B3-B238-23B24D99F957Q30425111-6C39F872-669A-4147-B129-98E8436BF2D8Q30429380-EB878EDD-A156-4B4C-A120-086E0FB1DFCBQ30433217-F6746A38-99E4-495A-AF48-1DBBA2416DEAQ30433911-A42305FE-9578-44BB-A97F-DCDBFD138B9DQ30434547-97E71B18-7DCB-426F-9CD0-CA14E273CB2EQ30435893-6D94DBB5-1F23-4F88-BA56-89A8B46CC240Q30436792-5872E5BF-A3BA-4003-BAAD-195EF77F122AQ30437794-1A68C41C-748B-4F6E-887E-3DBC41F80E06Q30438159-F23380F3-B616-4FFB-A56B-8242A5D1F0F4Q33406769-22E4AFBB-23F4-4242-8D03-C44EC46C1910Q33785368-97D3F8F0-C188-4D4D-97EF-934820C5449EQ34173622-651B00A6-2365-4D7F-BF14-A9936E91900AQ34580059-7BEE68C6-FFA8-49ED-B927-366C90FF6023Q34757171-F21D8256-8E42-4255-BCC0-2CD77B6E1535Q34801323-0253D14D-EBBF-497F-8B34-FF61D9305F3DQ35333587-FB528D9E-A867-46EF-BDDF-6463CEA78FBEQ36138007-0DBF9AC7-3698-41D0-A786-55EB2BEAC094Q36476100-CA775CE1-6E68-4F78-8918-EC32C4823D8AQ36739767-0815CF38-D4ED-4E57-BE1D-8ABF740B5C0AQ36981666-5319BAC6-6185-4B6E-942E-B32C702CECF6Q37259608-D5A104A9-AA10-4915-9711-516881627D1EQ37547268-D1C8967C-BD3C-46DA-82AD-8C9A5A25156AQ38050990-B8C187A7-2BC7-48DF-8E9B-D37B7D10D7ACQ38833090-C2AD47D3-CFEE-45A9-B2A7-6AF192E1AB92Q41497500-586FCE5A-2160-4904-AD9E-2F5ECB9C6BF4Q41859070-269E9B4F-F224-4C6A-BD18-D866CF2F3396Q53259763-77BB0E0E-7627-4357-A8D1-F8123032B7E3Q55001270-46CBF1DF-00EA-4B4B-B67B-F6ED1CF914EE
P2860
Immunity to melanoma antigens: from self-tolerance to immunotherapy.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Immunity to melanoma antigens: from self-tolerance to immunotherapy.
@ast
Immunity to melanoma antigens: from self-tolerance to immunotherapy.
@en
type
label
Immunity to melanoma antigens: from self-tolerance to immunotherapy.
@ast
Immunity to melanoma antigens: from self-tolerance to immunotherapy.
@en
prefLabel
Immunity to melanoma antigens: from self-tolerance to immunotherapy.
@ast
Immunity to melanoma antigens: from self-tolerance to immunotherapy.
@en
P2093
P50
P1476
Immunity to melanoma antigens: from self-tolerance to immunotherapy.
@en
P2093
Gina Petroni
Lisa Nichols
Mark Smolkin
Timothy N J Bullock
Walter Olson
William W Grosh
P304
P356
10.1016/S0065-2776(06)90007-8
P577
2006-01-01T00:00:00Z